Clinical Trial Update: Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing carboplatin and etoposide with or without oblimersen sodium in extensive-stage small cell lung cancer has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• Genasense (oblimersen)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 2 | Status: COMPLETED